background
cation
amphiphil
drug
inhibit
prolifer
type
fipv
vitro
studi
evalu
vivo
antivir
effect
administ
spf
cat
challeng
type
fipv
method
ten
spf
cat
randomli
assign
two
experiment
group
fipv
inocul
intraperiton
cat
control
group
administ
pb
group
administ
subcutan
mgkg
day
mgkg
day
viral
inocul
result
two
five
control
cat
administ
pb
alon
develop
fip
four
five
cat
administ
develop
sign
fip
one
cat
temporarili
develop
fever
clinic
symptom
gross
lesion
note
autopsi
end
experi
fipv
gene
detect
intermitt
fece
saliva
regardless
develop
fip
administr
conclus
administ
cat
experiment
infect
type
fipv
develop
fip
might
suppress
compar
control
group
howev
number
anim
fip
low
establish
antivir
effect
cat
coronavirus
singlestrand
positivesens
rna
virus
subfamili
coronavirina
famili
coronavirida
coronavirus
classifi
alpha
beta
gamma
deltacoronaviru
felin
coronaviru
fcov
belong
speci
alphacoronaviru
genu
alphacoronaviru
alphacoronaviru
also
includ
porcin
transmiss
gastroenter
viru
tgev
canin
coronaviru
ccov
fcov
virion
mainli
compos
nucleocapsid
n
envelop
e
membran
peplom
spike
protein
fcov
classifi
two
serotyp
type
ii
fcov
base
differ
sequenc
protein
region
genom
type
ii
fcov
aris
spontan
genom
recombin
type
fcov
type
ii
ccov
sever
serolog
genet
survey
report
type
fcov
preval
type
ii
therefor
case
fip
caus
type
fcov
infect
fip
typic
manifest
effus
accumul
granuloma
format
ascit
fluid
common
effus
cat
fip
follow
pleural
effus
granulomat
lesion
often
observ
surfac
sever
organ
includ
omentum
intestin
liver
kidney
spleen
lung
mortal
rate
cat
exhibit
symptom
high
recent
develop
treatment
fip
drug
resolv
symptom
fip
rate
expect
use
treatment
fip
inhibit
viral
protein
requir
prolifer
fipv
escap
viru
drug
may
appear
mutat
viral
protein
fact
pedersen
et
al
report
one
viru
resist
field
studi
therefor
new
drug
differ
mechan
action
drug
may
necessari
one
cation
amphiphil
drug
cad
cell
permeabl
suppress
function
niemannpick
protein
cholesterol
transport
prevent
releas
cholesterol
lysosom
report
antivir
effect
dengu
viru
denv
hepat
c
viru
hcv
zika
viru
zikv
chikungunya
viru
chikv
inhibit
biosynthesi
intracellular
transport
cholesterol
previous
report
also
inhibit
intracellular
transport
cholesterol
high
antiprolif
effect
type
fipv
noncytotox
concentr
felin
cell
line
base
result
promis
antivir
agent
type
fipv
howev
whether
also
antivir
effect
type
fipv
vivo
unknown
studi
evalu
vivo
antivir
effect
administ
spf
cat
challeng
type
fipv
experiment
schedul
inform
cat
indic
figur
tabl
respect
fipv
tcid
ml
inocul
intraperiton
specificpathogenfre
spf
cat
control
group
n
administ
pb
group
n
administ
subcutan
mgkg
day
mgkg
day
viral
inocul
cat
examin
daili
clinic
sign
bodi
temperatur
weight
measur
blood
collect
weekli
use
heparin
syring
viru
inocul
complet
differenti
cell
count
measur
addit
saliva
collect
everi
day
fece
collect
daili
preserv
analysi
c
fip
diagnos
confirm
upon
postmortem
examin
reveal
periton
pleural
effus
pyogranuloma
major
organ
cat
euthan
reach
human
endpoint
day
challeng
therefor
new
drug
differ
mechan
action
drug
may
necessari
one
cation
amphiphil
drug
cad
cell
permeabl
suppress
function
niemannpick
protein
cholesterol
transport
prevent
releas
cholesterol
lysosom
report
antivir
effect
dengu
viru
denv
hepat
c
viru
hcv
zika
viru
zikv
chikungunya
viru
chikv
inhibit
biosynthesi
intracellular
transport
cholesterol
previous
report
also
inhibit
intracellular
transport
cholesterol
high
antiprolif
effect
type
fipv
noncytotox
concentr
felin
cell
line
base
result
promis
antivir
agent
type
fipv
howev
whether
also
antivir
effect
type
fipv
vivo
unknown
studi
evalu
vivo
antivir
effect
administ
spf
cat
challeng
type
fipv
experiment
schedul
inform
cat
indic
figur
tabl
respect
fipv
ml
inocul
intraperiton
specificpathogenfre
spf
cat
control
group
n
administ
pb
group
n
administ
subcutan
mgkg
day
mgkg
day
viral
inocul
cat
examin
daili
clinic
sign
bodi
temperatur
weight
measur
blood
collect
weekli
use
heparin
syring
viru
inocul
complet
differenti
cell
count
measur
addit
saliva
collect
everi
day
fece
collect
daili
preserv
analysi
fip
diagnos
confirm
upon
postmortem
examin
reveal
periton
pleural
effus
pyogranuloma
major
organ
cat
euthan
reach
human
endpoint
day
challeng
bodi
temperatur
measur
serial
cat
challeng
fipv
control
group
cat
develop
fever
c
day
postinfect
dpi
dpi
respect
figur
persist
human
endpoint
addit
cat
develop
fever
c
dpi
group
cat
develop
fever
c
dpi
fever
persist
dpi
began
declin
dpi
recur
end
experi
cat
exhibit
fever
c
throughout
experi
bodi
weight
cat
measur
challeng
fipv
cat
hich
develop
fip
bodi
weight
decreas
week
human
endpoint
figur
cat
develop
fip
bodi
weight
cat
decreas
dpi
ut
increas
thereaft
recov
end
experi
level
viral
challeng
n
cat
littl
chang
bodi
weight
note
throughout
experi
bodi
weight
cat
measur
challeng
fipv
cat
develop
fip
bodi
weight
decreas
week
human
endpoint
figur
cat
develop
fip
bodi
weight
cat
decreas
dpi
increas
thereaft
recov
end
experi
level
viral
challeng
cat
littl
chang
bodi
weight
note
throughout
experi
antifcov
antibodi
assay
elisa
use
fipv
antigen
figur
cat
antifcov
antibodi
increas
serial
dpi
peripher
blood
lymphocyt
count
examin
cat
challeng
fipv
cat
lymphocyt
count
decreas
dpi
figur
dpi
peripher
blood
lymphocyt
antifcov
antibodi
assay
elisa
use
fipv
antigen
figur
cat
antifcov
antibodi
increas
serial
dpi
antifcov
antibodi
assay
elisa
use
fipv
antigen
figur
cat
antifcov
antibodi
increas
serial
dpi
peripher
blood
lymphocyt
count
examin
cat
challeng
fipv
cat
lymphocyt
count
decreas
dpi
figur
dpi
peripher
blood
lymphocyt
count
cat
remain
low
human
endpoint
cat
except
cat
peripher
blood
lymphocyt
count
chang
within
normal
rang
peripher
blood
lymphocyt
count
examin
cat
challeng
fipv
cat
lymphocyt
count
decreas
dpi
figur
dpi
peripher
blood
lymphocyt
count
cat
remain
low
human
endpoint
cat
except
cat
peripher
blood
lymphocyt
count
chang
within
normal
rang
laboratori
pathogen
x
peer
review
figur
chang
lymphocyt
count
fipvinfect
cat
cat
euthan
clinic
condit
reach
human
endpoint
examin
viral
shed
inocul
fipv
nestedrtpcr
target
fipv
n
gene
perform
figur
sensit
nestedrtpcr
assess
use
purifi
type
fipv
rna
compar
ct
quantit
real
time
rtpcr
rtqpcr
target
fipv
report
kim
et
al
nestedrtpcr
demonstr
higher
detect
sensit
rtqpcr
figur
base
result
nestedrtpcr
use
detect
viral
gene
examin
viral
shed
inocul
fipv
nestedrtpcr
target
fipv
n
gene
perform
figur
sensit
nestedrtpcr
assess
use
purifi
type
fipv
rna
compar
ct
quantit
real
time
rtpcr
rtqpcr
target
examin
viral
shed
inocul
fipv
nestedrtpcr
target
fipv
n
gene
perform
figur
sensit
nestedrtpcr
assess
use
purifi
type
fipv
rna
compar
ct
quantit
real
time
rtpcr
rtqpcr
target
fipv
report
kim
et
al
nestedrtpcr
demonstr
higher
detect
sensit
rtqpcr
figur
base
result
nestedrtpcr
use
detect
viral
gene
anim
use
experi
euthan
day
human
endpoint
judg
reach
plot
surviv
curv
figur
control
group
cat
euthan
dpi
cat
dpi
respect
group
none
cat
develop
fip
surviv
incid
fip
control
cat
group
incid
fip
suspect
cat
judg
reach
plot
surviv
curv
figur
control
group
cat
euthan
dpi
cat
dpi
respect
group
none
cat
develop
fip
surviv
incid
fip
control
cat
group
incid
fip
suspect
cat
one
spf
cat
administ
singl
dose
monocyt
spf
cat
administr
intracellular
cholesterol
diffus
entir
cytoplasm
figur
monocyt
spf
cat
h
administr
cholesterol
found
aggreg
cytoplasm
one
spf
cat
administ
singl
dose
monocyt
spf
cat
administr
intracellular
cholesterol
diffus
entir
cytoplasm
figur
monocyt
spf
cat
h
administr
cholesterol
found
aggreg
cytoplasm
figur
local
intracellular
cholesterol
peripher
blood
monocyt
spf
cat
administ
singl
dose
mgkg
administ
spf
cat
peripher
blood
collect
h
administr
intracellular
cholesterol
mononuclear
cell
includ
peripher
blood
monocyt
stain
filipin
iii
nucleu
stain
propidium
iodid
pi
arrowhead
peripher
blood
monocyt
virus
use
cholesterol
infect
host
cell
accumul
intracellular
cholesterol
suppress
function
cholesterol
transport
prolifer
denv
hcv
zikv
chikv
suppress
previous
report
suppress
prolifer
type
fipv
inhibit
intracellular
transport
cholesterol
felin
cell
line
howev
vivo
effect
remain
unclear
studi
administ
cat
evalu
inhibitori
effect
cholesterol
transport
whether
antivir
effect
fipv
report
administr
cat
pharmacokinet
cat
unknown
rat
howev
pharmacokinet
administr
previous
investig
distribut
brain
immedi
subcutan
intraperiton
administr
rat
demonstr
biphas
elimin
pattern
consist
earlyrapid
clearanc
h
h
administr
subsequ
slow
sustain
clearanc
h
base
report
assum
distribut
volum
cat
mlkg
set
singl
dosag
necessari
obtain
initi
figur
local
intracellular
cholesterol
peripher
blood
monocyt
spf
cat
administ
singl
dose
mgkg
administ
spf
cat
peripher
blood
collect
h
administr
intracellular
cholesterol
mononuclear
cell
includ
peripher
blood
monocyt
stain
filipin
iii
nucleu
stain
propidium
iodid
pi
arrowhead
peripher
blood
monocyt
virus
use
cholesterol
infect
host
cell
accumul
intracellular
cholesterol
suppress
function
cholesterol
transport
prolifer
denv
hcv
zikv
chikv
suppress
previous
report
suppress
prolifer
type
fipv
inhibit
intracellular
transport
cholesterol
felin
cell
line
howev
vivo
effect
remain
unclear
studi
administ
cat
evalu
inhibitori
effect
cholesterol
transport
whether
antivir
effect
fipv
report
administr
cat
pharmacokinet
cat
unknown
rat
howev
pharmacokinet
administr
previous
investig
distribut
brain
immedi
subcutan
intraperiton
administr
rat
demonstr
biphas
elimin
pattern
consist
earlyrapid
clearanc
h
h
administr
subsequ
slow
sustain
clearanc
h
base
report
assum
distribut
volum
cat
mlkg
set
singl
dosag
necessari
obtain
initi
blood
concentr
mgkg
cat
administ
dose
blood
concentr
estim
reach
within
h
administr
concentr
time
higher
ec
type
fipv
determin
vitro
experi
administ
spf
cat
examin
whether
intracellular
cholesterol
aggreg
peripher
blood
monocyt
monocyt
spf
cat
administr
intracellular
cholesterol
diffus
entir
cytoplasm
monocyt
spf
cat
h
administr
cholesterol
found
aggreg
cytoplasm
monocyt
spf
cat
administ
intracellular
cholesterol
accumul
induc
vivo
antivir
effect
examin
administ
spf
cat
experiment
infect
type
fipv
challeng
type
fipv
administ
mgkg
mgkg
twice
thereaft
interv
epilept
symptom
note
cat
administ
total
three
time
therefor
administr
method
employ
studi
suggest
safe
cat
howev
consider
studi
drug
fip
necessari
administ
long
period
fip
remiss
amphiphil
like
accumul
brain
adipos
tissu
inde
epilept
symptom
report
induc
rat
repetit
administr
high
dose
mgkg
avoid
advers
effect
necessari
investig
pharmacokinet
cat
greater
detail
one
week
viral
inocul
peripher
blood
lymphocyt
count
decreas
antifcov
antibodi
increas
cat
five
control
cat
administ
pb
alon
two
exhibit
persist
fever
bodi
weight
loss
loss
appetit
subsequ
develop
fip
two
cat
improv
fip
symptom
euthan
howev
five
cat
administ
four
develop
sign
fip
one
cat
temporarili
develop
fever
clinic
symptom
gross
lesion
note
autopsi
end
experi
incid
fip
control
two
five
cat
group
incid
fip
zero
suspect
one
five
cat
previou
experi
fipv
caus
fip
rate
intraperiton
inocul
base
fact
might
suppress
develop
fip
fipvinfect
cat
howev
number
anim
fip
low
establish
antivir
effect
cat
compar
effect
antivir
drug
seem
weak
antivir
effect
vivo
viral
inocul
sampl
serial
collect
control
group
analyz
detect
fipv
n
gene
fipv
n
gene
detect
intermitt
fece
saliva
regardless
develop
fip
administr
pedersen
et
al
report
viral
gene
rare
detect
tissu
directli
involv
viral
prolifer
fece
blood
also
suggest
whether
viral
gene
detect
unrel
patholog
manifest
fip
observ
suggest
difficult
evalu
vivo
prolifer
type
fipv
cat
use
fece
saliva
plasma
sampl
although
collect
continu
minim
noninvas
procedur
accord
pedersen
et
al
viral
gene
readili
detect
tissu
close
relat
viral
prolifer
omentum
mesenter
lymph
node
spleen
effus
among
effus
type
periton
effus
particular
collect
rel
easili
inde
compound
antiprolif
effect
fipv
confirm
antivir
effect
base
measur
amount
viral
gene
periton
effus
cat
develop
fip
howev
use
evalu
method
limit
cat
develop
fip
periton
effus
futur
develop
exact
simpl
method
measur
amount
viru
anticip
suggest
suppress
prolifer
type
fipv
vivo
reduc
incid
fip
ie
promis
antifipv
drug
previous
report
itraconazol
drug
suppress
prolifer
type
fipv
inhibit
intracellular
cholesterol
transport
similarli
itraconazol
use
clinic
veterinari
practic
antifung
agent
promptli
appli
cat
furthermor
si
valu
cc
ec
higher
itraconazol
suggest
clinic
safer
itraconazol
antifipv
drug
addit
antivir
agent
high
bloodbrain
barrier
penetr
may
necessari
improv
condit
fip
cat
exhibit
central
nervou
system
symptom
highli
transfer
brain
may
also
effect
manag
neurolog
symptom
fip
observ
along
itraconazol
consid
potenti
antivir
agent
applic
type
fipv
studi
administ
cat
evalu
inhibitori
effect
cholesterol
transport
antivir
effect
fipv
administ
cat
induc
cholesterol
accumul
cytoplasm
peripher
blood
monocyt
administ
cat
experiment
infect
type
fipv
develop
fip
might
suppress
compar
control
group
howev
number
anim
fip
low
establish
antivir
effect
cat
futur
necessari
examin
pharmacokinet
cat
evalu
therapeut
effect
cat
diagnos
fip
type
fipv
grown
feli
catu
whole
fetu
fcwf
cell
c
type
fipv
isol
laboratori
purchas
sigma
aldrich
st
lui
mo
usa
dissolv
phosphatebuff
salin
pb
ph
mgml
steril
filter
filter
applic
nation
institut
guidelin
care
use
anim
follow
anim
experiment
protocol
approv
presid
kitasato
univers
judgment
institut
anim
care
use
committe
kitasato
univers
approv
spf
cat
bred
laboratori
maintain
temperaturecontrol
isol
facil
elisa
antifcov
antibodi
perform
describ
takano
et
al
briefli
detergentdisrupt
purifi
fipv
virion
dilut
appropri
carbon
buffer
ph
total
dilut
pipet
well
flatbottom
plate
plate
allow
stand
overnight
c
wash
pb
contain
test
plasma
sampl
ad
well
horseradish
peroxidaseconjug
goat
anticat
igg
icn
pharmaceut
inc
costa
mesa
ca
usa
dilut
optim
concentr
pb
contain
fc
dilut
ad
well
plate
incub
c
min
substrat
solut
ad
well
plate
incub
c
min
dark
room
substrat
solut
prepar
dissolv
ophenylenediamin
dihydrochlorid
concentr
mgml
citric
acid
na
hpo
buffer
ph
h
ad
reaction
stop
n
h
solut
optic
densiti
od
nm
determin
total
cellular
rna
extract
fece
saliva
plasma
use
high
pure
rna
isol
kit
roch
diagnost
gmbh
mannheim
germani
accord
instruct
manufactur
rna
dissolv
elut
buffer
use
total
cellular
rna
templat
cdna
synthes
use
strand
cdna
synthesi
kit
takara
bio
inc
kusatsu
japan
revers
transcript
perform
final
volum
contain
oligo
dt
primer
result
solut
incub
c
min
synthes
cdna
cdna
amplifi
nestedpcr
use
specif
primer
felin
fipv
n
gene
primer
sequenc
shown
tabl
pcr
perform
total
volum
one
microlit
sampl
cdna
mix
quick
taq
hs
dyemix
toyobo
co
osaka
japan
primer
mix
distil
water
use
pcr
thermal
cycler
dice
takara
bio
inc
kusatsu
japan
dna
amplifi
c
min
follow
cycl
denatur
c
min
primer
anneal
c
min
synthesi
c
min
final
extens
c
min
round
pcr
perform
thermal
protocol
pcr
product
resolv
electrophoresi
agaros
gel
gel
incub
ethidium
bromid
solut
band
visual
use
uv
transillumin
nm
photograph
compar
sensit
nestedrtpcr
rtqpcr
perform
use
primer
target
utr
report
kim
et
al
briefli
rna
reversetranscrib
amplifi
use
rnadirect
realtim
pcr
master
mix
toyobo
co
osaka
japan
specif
primer
utrf
utrr
probe
reaction
carri
total
volum
pcr
plate
use
stepon
realtim
pcr
system
thermo
fisher
scientif
waltham
usa
c
c
min
c
min
follow
cycl
c
c
min
nestedrtpcr
rtqpcr
perform
sensit
compar
templat
rna
purifi
cultur
supernat
type
fipv
use
cat
administ
subcutan
mgkg
peripher
blood
collect
h
administr
heparin
blood
dilut
pb
subject
ficollhypaqu
lymphoprep
aler
technolog
oslo
norway
densiti
gradient
centrifug
g
min
pbmc
layer
collect
wash
three
time
cell
count
pbmc
seed
labtek
chamber
slide
thermo
fisher
scientif
waltham
usa
densiti
cellswel
slide
incub
c
h
wash
three
time
adher
cell
fix
stain
cellular
cholesterol
stain
cholesterol
cell
base
detect
assay
kit
cayman
chemic
ann
arbor
mi
usa
accord
manufactur
instruct
filipin
iii
stain
cell
stain
propidium
iodid
pi
nacalai
tesqu
inc
kyoto
japan
analyz
use
leica
microscop
la
x
integr
imag
system
leica
microsystem
wetzlar
germani
